Feasibility of Measuring Preferences for Chemotherapy Among Early-Stage Breast Cancer Survivors Using a Direct Rank Ordering Multicriteria Decision Analysis Versus a Time Trade-Off.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: Adis, Springer International Country of Publication: New Zealand NLM ID: 101309314 Publication Model: Print Cited Medium: Internet ISSN: 1178-1661 (Electronic) Linking ISSN: 11781653 NLM ISO Abbreviation: Patient Subsets: MEDLINE
    • Publication Information:
      Publication: Auckland : Adis, Springer International
      Original Publication: Chester, UK : Wolters Kluwer Health/Adis
    • Subject Terms:
      Decision Support Techniques* ; Patient Preference*; Breast Neoplasms/*drug therapy ; Breast Neoplasms/*pathology ; Cancer Survivors/*psychology; Adult ; Aged ; California ; Feasibility Studies ; Female ; Humans ; Middle Aged ; Registries
    • Abstract:
      Objectives: Chemotherapy is increasingly a preference-based choice among women diagnosed with early-stage breast cancer. Multicriteria decision analysis (MCDA) is a promising but underutilized method to facilitate shared decision making. We explored the feasibility of conducting an MCDA using direct rank ordering versus a time trade-off (TTO) to assess chemotherapy choice in a large population-based sample.
      Methods: We surveyed 904 early-stage breast cancer survivors who were within 5 years of diagnosis and reported to the Western Washington State Cancer System and Kaiser Permanente Northern California registries. Direct rank ordering of 11 criteria and TTO surveys were conducted from September 2015 to July 2016; clinical data were obtained from registries or medical records. Multivariable regressions estimated post hoc associations between the MCDA, TTO, and self-reported chemotherapy receipt, considering covariates.
      Results: Survivors ranged in age from 25 to 74 years and 73.9% had stage I tumors. The response rate for the rank ordering was 81.0%; TTO score was 94.2%. A one-standard deviation increase in the difference between the chemotherapy and no chemotherapy MCDA scores was associated with a 75.1% (95% confidence interval 43.9-109.7%; p < 0.001) increase in the adjusted odds of having received chemotherapy; no association was found between the TTO score and chemotherapy receipt.
      Conclusions: A rank-order-based MCDA was feasible and was associated with chemotherapy choice. Future research should consider developing and testing this MCDA for use in clinical encounters. Additional research is required to develop a TTO-based model and test its properties against a pragmatic MCDA to inform future shared decision-making tools.
    • Comments:
      Comment in: Patient. 2021 Jan;14(1):145-146. (PMID: 33169314)
    • References:
      J Clin Oncol. 2010 Jul 1;28(19):3146-53. (PMID: 20516438)
      Patient. 2019 Dec;12(6):559-569. (PMID: 31321706)
      Ann Oncol. 2005 Nov;16(11):1786-94. (PMID: 16126738)
      PLoS One. 2015 May 22;10(5):e0126625. (PMID: 26000636)
      Value Health. 2016 Jan;19(1):1-13. (PMID: 26797229)
      Value Health. 2018 Apr;21(4):394-397. (PMID: 29680094)
      Am J Manag Care. 2016 May 01;22(5):e153-60. (PMID: 27266581)
      Science. 1974 Sep 27;185(4157):1124-31. (PMID: 17835457)
      J Clin Oncol. 2018 Feb 20;36(6):554-562. (PMID: 29309250)
      Health Serv Res. 1972 Summer;7(2):118-33. (PMID: 5044699)
      Value Health. 2012 Dec;15(8):1172-81. (PMID: 23244821)
      Breast. 2019 Nov;48 Suppl 1:S115-S118. (PMID: 31839151)
      Patient. 2010;3(4):229-248. (PMID: 21394218)
      Value Health. 2016 Mar-Apr;19(2):125-37. (PMID: 27021745)
      Breast Cancer Res Treat. 2019 Jan;173(2):417-427. (PMID: 30306429)
      Eur J Health Econ. 2013 Jul;14 Suppl 1:S53-64. (PMID: 23900665)
      JCO Clin Cancer Inform. 2018 Dec;2:1-10. (PMID: 30652607)
      Med Decis Making. 2014 Aug;34(6):746-55. (PMID: 24300851)
      Pharmacoeconomics. 2014 Apr;32(4):345-65. (PMID: 24504851)
      JCO Oncol Pract. 2020 Feb;16(2):e148-e154. (PMID: 31815575)
      Breast Cancer Res Treat. 2019 Nov;178(1):1-15. (PMID: 31342311)
      N Engl J Med. 2018 Jul 12;379(2):111-121. (PMID: 29860917)
      Nature. 2017 Jan 10;541(7636):151-153. (PMID: 28079088)
      N Engl J Med. 2015 Nov 19;373(21):2005-14. (PMID: 26412349)
      Med Decis Making. 2019 May;39(4):437-449. (PMID: 31117875)
      J Natl Cancer Inst Monogr. 2001;(30):146-52. (PMID: 11773309)
      Patient. 2012;5(1):45-56. (PMID: 22185216)
      Value Health. 2017 Feb;20(2):251-255. (PMID: 28237204)
      Pharmacoeconomics. 2019 Dec;37(12):1417-1419. (PMID: 31565761)
      Breast Cancer Res Treat. 2017 May;163(1):167-176. (PMID: 28224383)
    • Grant Information:
      U01 CA152958 United States CA NCI NIH HHS; U01 CA 152958 United States CA NCI NIH HHS; R35CA197289 United States CA NCI NIH HHS; UO1CA183081 United States CA NCI NIH HHS; U01 CA183081 United States CA NCI NIH HHS; R35 CA197289 United States CA NCI NIH HHS
    • Publication Date:
      Date Created: 20200525 Date Completed: 20210726 Latest Revision: 20210726
    • Publication Date:
      20231215
    • Accession Number:
      PMC8252921
    • Accession Number:
      10.1007/s40271-020-00423-w
    • Accession Number:
      32447608